Applied Nanotech Awarded Patent for EZKnowz(TM), a Multiple-Gas Breath Sensor for the Detection of Potential Disease States

Appoints Dr. Royce Johnson to Accelerate Business Development in Medical Sectors


AUSTIN, Texas, Dec. 7, 2011 (GLOBE NEWSWIRE) -- Applied Nanotech Holdings, Inc. (OTCBB:APNT) is pleased to announce that it has been awarded European Patent EP1976431B1, for its EZKnowz™, a multiple-gas breath sensor for use in medical applications for the detection of potential disease states. This patent covers the complete EZKnowz™ sensor platform, including a sample collector, analysis device and data storage device.

The EZKnowz™ sensor platform, developed by Applied Nanotech, combines existing differential ion mobility spectrometry technology with Applied Nanotech's proprietary non-radioactive ion source. The EZKnowz™ sensor platform is capable of sensing a broad range of gas species and selecting specific gasses in a complex environment. The levels of detection of the EZKnowz™ sensor platform for many gasses are on the range of parts per billion (one or more molecules in a concentration of one billion other gas molecules) and in some cases, in the range of parts per trillion, sufficient for many applications.

Unlike other breath detection systems on the market that are limited to centralized laboratories or facilities because of their size, EZKnowz™ is a compact, portable system that can be used in a variety of settings, including laboratories, doctor's offices and home-health environments.  EZKnowz™ has the potential to detect a variety gases and diseases, including Mercaptan/BTEX, lung cancer detection, influenza detection, pharmaceutical contamination, wound healing/infection detection and plant disease detection. In addition, EZKnowz™ has been shown to identify body odor biometrics for use in military and homeland security applications, including the detection of explosives.

Applied Nanotech is also pleased to announce that it has hired Dr. Royce Johnson to accelerate its business development initiatives in medical sectors. Dr. Johnson spent 14 years with therapeutic medical device developer, Kinetic Concepts, Inc. (KCI), where he was instrumental in developing and commercializing breakthrough developments revolutionizing wound therapy, tissue engineering, skin grafting, phototherapy, and therapeutic hypothermia. Dr. Johnson was twice recognized by Frost & Sullivan as their Most Valuable Thought Leader in MindXchange Programs. He earned his bachelor's, master's, and doctoral degrees in biology and bioengineering at the University of Utah and holds a certificate in strategy and innovation from MIT Sloan School of Management.

About APPLIED NANOTECH HOLDINGS, INC.

Applied Nanotech Holdings, Inc. is a global nanotechnology leader, focused on solving problems at the molecular level, and commercializing the results of its research. Its team of PhD-level scientists and engineers work with companies and other organizations to solve technical impasses and create innovations that will create a competitive advantage. The business model is to sell products and license patents and technology to partners that will manufacture and distribute products using the technology. Applied Nanotech has over 300 patents or patents pending. Applied Nanotech's website is http://www.appliednanotech.net.

SAFE HARBOR STATEMENT

This press release contains forward-looking statements that involve risks and uncertainties concerning our business, products, and financial results. Actual results may differ materially from the results predicted. More information about potential risk factors that could affect our business, products, and financial results are included in our annual report on Form 10-K for the fiscal year ended December 31, 2010, and in reports subsequently filed by us with the Securities and Exchange Commission ("SEC"). All documents are available through the SEC's Electronic Data Gathering Analysis and Retrieval System (EDGAR) at www.sec.gov or from our website listed above. We hereby disclaim any obligation to publicly update the information provided above, including forward-looking statements, to reflect subsequent events or circumstances.


            

Contact Data